You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Medtronic
McKesson
Boehringer Ingelheim
Merck
Harvard Business School
Mallinckrodt

Last Updated: May 8, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR XTANDI

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Xtandi

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00510718 A Phase 1 Study of MDV3100 in Patients With Castration-Resistant (Hormone-Refractory) Prostate Cancer Active, not recruiting Medivation, Inc. Phase 1 2007-07-01 This is a multi-center open-label dose-escalation study of a novel compound (MDV3100) to treat patients with castration-resistant (hormone-refractory) prostate cancer. Additional patients will be enrolled in expanded cohorts at doses determined to be tolerable. Patients who tolerate the drug and do not progress will be allowed to continue to look for PSA response.
NCT01302041 A Study to Test if Enzalutamide is Effective and Safe in Prostate Cancer Patients Who Have Never Had Hormone Therapy Active, not recruiting Medivation, Inc. Phase 2 2011-05-01 To evaluate the effect of enzalutamide on prostate specific antigen (PSA) level in men with prostate cancer.
NCT01302041 A Study to Test if Enzalutamide is Effective and Safe in Prostate Cancer Patients Who Have Never Had Hormone Therapy Active, not recruiting Astellas Pharma Inc Phase 2 2011-05-01 To evaluate the effect of enzalutamide on prostate specific antigen (PSA) level in men with prostate cancer.
NCT01534052 A Study to Assess the Safety of Continued Administration of MDV3100 in Subjects With Prostate Cancer Who Showed Benefit From Prior Exposure to MDV3100 Active, not recruiting Medivation, Inc. Phase 2 2011-11-01 A study to assess the safety of continued administration of MDV3100 in subjects with Prostate Cancer who have already undergone treatment with MDV3100 and showed benefit.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Xtandi

Condition Name

Condition Name for Xtandi
Intervention Trials
Prostate Cancer 31
Stage IV Prostate Cancer 13
Metastatic Prostate Carcinoma 9
Prostate Adenocarcinoma 8
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Xtandi
Intervention Trials
Prostatic Neoplasms 102
Adenocarcinoma 17
Carcinoma 13
Breast Neoplasms 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Xtandi

Trials by Country

Trials by Country for Xtandi
Location Trials
United States 336
Canada 42
United Kingdom 37
Italy 36
Spain 34
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Xtandi
Location Trials
California 26
New York 23
Texas 20
Maryland 17
Illinois 15
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Xtandi

Clinical Trial Phase

Clinical Trial Phase for Xtandi
Clinical Trial Phase Trials
Phase 4 9
Phase 3 13
Phase 2/Phase 3 1
[disabled in preview] 58
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Xtandi
Clinical Trial Phase Trials
Recruiting 57
Not yet recruiting 33
Active, not recruiting 20
[disabled in preview] 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Xtandi

Sponsor Name

Sponsor Name for Xtandi
Sponsor Trials
Medivation, Inc. 40
Astellas Pharma Inc 28
National Cancer Institute (NCI) 20
[disabled in preview] 11
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Xtandi
Sponsor Trials
Industry 130
Other 98
NIH 20
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Baxter
AstraZeneca
Moodys
McKinsey
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.